ANAB / AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative more_horizontal

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative more_horizontal

AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study. more_horizontal

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative more_horizontal

AnaptysBio, Inc. had major deals with big pharma in past years. However, its current programs are not that convincing. They have a lot of cash from ea more_horizontal

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to los more_horizontal

US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and tak more_horizontal

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative more_horizontal